FGI-106
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | 501081-38-5 |
PubChem (CID) | 432342 |
ChemSpider | 382357 |
Chemical and physical data | |
Formula | C28H38N6 |
Molar mass | 458.640 |
3D model (Jmol) | Interactive image |
| |
|
FGI-106 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped RNA viruses, in particular viral hemorrhagic fevers from the bunyavirus, flavivirus and filovirus families. It acts as an inhibitor which blocks viral entry into host cells. In animal tests FGI-106 shows both prophylactic and curative action against a range of deadly viruses for which few existing treatments are available, including the bunyaviruses Hantavirus, Rift Valley fever virus and Crimean-Congo hemorrhagic fever virus, the flavivirus Dengue virus, and the filoviruses Ebola virus and Marburg virus.[1][2][3][4][5]
See also
References
- ↑ Aman, M. J.; Kinch, M. S.; Warfield, K.; Warren, T.; Yunus, A.; Enterlein, S.; Stavale, E.; Wang, P.; Chang, S.; Tang, Q. (2009). "Development of a broad-spectrum antiviral with activity against Ebola virus". Antiviral Research. 83 (3): 245–251. doi:10.1016/j.antiviral.2009.06.001.
- ↑ Kinch (2010). "Development of FGI-106 as a broad-spectrum therapeutic with activity against members of the family Bunyaviridae". Virus Adaptation and Treatment: 9. doi:10.2147/VAAT.S6903.
- ↑ Basu, A.; Li, B.; Mills, D. M.; Panchal, R. G.; Cardinale, S. C.; Butler, M. M.; Peet, N. P.; Majgier-Baranowska, H.; Williams, J. D.; Patel, I.; Moir, D. T.; Bavari, S.; Ray, R.; Farzan, M. R.; Rong, L.; Bowlin, T. L. (2011). "Identification of a Small-Molecule Entry Inhibitor for Filoviruses". Journal of Virology. 85 (7): 3106–3119. doi:10.1128/JVI.01456-10.
- ↑ Ippolito, G.; Feldmann, H.; Lanini, S.; Vairo, F.; Di Caro, A.; Capobianchi, M.; Nicastri, E. (2012). "Viral hemorrhagic fevers: Advancing the level of treatment". BMC Medicine. 10: 31. doi:10.1186/1741-7015-10-31. PMC 3325866. PMID 22458265.
- ↑ Picazo E, Giordanetto F. Small molecule inhibitors of ebola virus infection. Drug Discovery Today February 2015, 20(2):277–286. doi:10.1016/j.drudis.2014.12.010
This article is issued from Wikipedia - version of the 8/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.